Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation (Q38078436)

28 August 2017

1 reference

title

Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation (English)

1 reference

28 August 2017

1 reference

1 reference

1 reference

1 reference

André J Scheen

1

1 reference

PubMed ID

23373842

28 August 2017

language of work or name

English

0 references

publication date

4 February 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

1 reference

28 August 2017

9

1 reference

28 August 2017

363-377

1 reference

28 August 2017

3

1 reference

Oral antidiabetic agents. A guide to selection

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Addition of incretin therapy to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

beta-cell failure in diabetes and preservation by clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Hypoglycaemia in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Drug interactions of clinical importance with antihyperglycaemic agents: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Metformin + saxagliptin for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Fixed-dose single tablet antidiabetic combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Linagliptin: in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Review of linagliptin for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Linagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Use of metformin in the setting of mild-to-moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Clinical pharmacokinetics of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Clinical Pharmacokinetics of Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Kidney function and age are both predictors of pharmacokinetics of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Metformin pathways: pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Polymorphism in human organic cation transporters and metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Cellular and molecular mechanisms of metformin: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.767892

10.1517/17425255.2013.767892

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23373842